Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 June;61(3) > Minerva Cardioangiologica 2013 June;61(3):323-31

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Minerva Cardioangiologica 2013 June;61(3):323-31

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Mesoglycan treatment in Raynaud phenomenon: a case series

Di Biase A.

Ambulatory of Vascular Diagnostic, Geriatric Medicine Villa Verde, Taranto, Italy


PDF


Aim and methods: Raynaud’s phenomenon (RP) is a common clinical disorder without cure or gold standard therapy. Mesoglycan is an well-balanced extract of glycosaminoglycans active on endothelial layers at microcirculatory level. Herein we investigated for the first time the efficacy and tolerability of mesoglycan on vasospastic attacks and videocapillaroscopy patterns in 25 consecutive patients with primary or secondary RP.
Results and conclusion: During 12 months of add-on therapy, mesoglycan obtained a remarkable and significant reduction in the frequency of Raynaud attacks and an improvement of the capillaroscopy abnormalities in most patients, without important adverse effects, revealing a good convenience in the management if this condition.

top of page